Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 978 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 Tables Turned June 23, 2020 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Connecting and Celebrating December 23, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
